FDA Accepts BioCardia's Pre-Submission for Helix Cardiac Delivery Catheter
Event summary
- FDA accepted BioCardia's pre-submission package for its Helix Transendocardial Delivery Catheter on March 17, 2026.
- CDRH will lead the review in consultation with CBER, acknowledging the CardiAMP Cell Therapy Breakthrough Designation.
- Helix is designed for minimally invasive intramyocardial delivery of therapeutic and diagnostic agents.
- Approval could enhance the pathway for BioCardia's CardiAMP Cell Therapy for ischemic heart failure.
The big picture
BioCardia's FDA pre-submission acceptance for Helix marks a critical step in advancing cardiac cell, gene, and protein therapeutics. The FDA's acknowledgment of the CardiAMP Breakthrough Designation underscores the strategic importance of Helix in enabling targeted, minimally invasive treatments. This development could position BioCardia as a key player in the evolving landscape of cardiovascular disease management, particularly in ischemic heart failure and chronic myocardial ischemia.
What we're watching
- Regulatory Momentum
- How the FDA's acceptance of the pre-submission package will accelerate the approval timeline for Helix.
- Strategic Synergies
- Whether the Helix approval will streamline the pathway for BioCardia's CardiAMP Cell Therapy.
- Market Differentiation
- The pace at which Helix could become the standard for minimally invasive cardiac agent delivery.
Our editorial coverage:
Related topics